A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines

Breast Journal

Volumn 19, Issue 3, 2013, Pages 240-249

  Campone, Mario ^a   Dobrovolskaya, Natalya ^b   Tjulandin, Serjei ^c   Chen, Shin Chen ^d   Fourie, Sameul ^e   Mefti, Fawzia ^f   Konstantinova, Maria ^g   Lefresne, Florence ^h   Meheust, Nadege ^h   Jassem, Jacek ⁱ  

^a UMR INSERM 892 ^*  (France)

^b Russian Research Center of Roentgenoradiology   (Russian Federation)

^c Russian Oncology Center   (Russian Federation)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e Wilmed Park Oncology ^*  (South Africa)

^f CENTRE RENÉ HUGUENIN   (France)

^g Moscow City Oncological Dispensary   (Russian Federation)

^h INSTITUT DE RECHERCHE PIERRE FABRE   (France)

ⁱ MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

capecitabine; combination; docetaxel; metastatic breast cancer; oral vinorelbine; sequential

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; DEXAMETHASONE; DOCETAXEL; NAVELBINE; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; ADULT; ALOPECIA; ARTHRALGIA; ASTHENIA; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; INFECTION; LACRIMATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; TAXOIDS; VINBLASTINE;

EID: 84876808350     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12098     Document Type: Review

References (22)

1. Jensen BV,. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Semin Oncol 2006; 33: S15-21.
2. Gralow JR,. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat 2005; 89: S9-15.
3. Piccart MJ, Burzykowski T, Buyse M, et al,. Taxanes alone or in combinations with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008; 26: 1980-6.
4. O'Shaughnessy J, Blum JL,. Capecitabine/taxanes combination therapy: evolving clinical utility in breast cancer. Clin Breast Cancer 2006; 7: 42-50.
5. O'Shaughnessy J, Miles D, Vukeljas S, et al,. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 12: 2812-23.
6. Nolé F, Catania G, Senna G, et al,. Oral vinorelbine in combination with capecitabine: phase I study in patients with metastatic breast cancer. Eur J Cancer 2004; 2 (suppl 2): 134 (abstr 269).
7. Liu G, Franssen E, Fitch M, Warner E,. Patient preferences for oral vs intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-5.
8. Therasse P, Arbuck SG, Eisenhauer EA, et al,. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000; 92: 205-16.
9. Pizzo PA,. Management of fever in patients with cancer and treatment induced neutropenia. New Engl J Med 1993; 328: 1323-32.
10. Fleming TR,. One-sample multiple testing procedure for Phase II clinical trials. Biometrics 1982; 38: 143-51.
11. Nolé F, Crivellari D, Mattioli R, et al,. Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 2009; 64: 676-80.
12. Tubiana-Mathieu N, Bougnoux P, Becquart D, et al,. All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International phase II Trial. Br J Cancer 2009; 101: 232-37.
13. Cardoso F, Bedard PL, Winer EP, et al,. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 2009; 101: 1174-81.
14. Sledge GW, Neuberg D, Bernado P, et al,. Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003; 21: 588-92.
15. Soto C, Torrecillas L, Reyes S, et al,. Capecitabine (X) and taxanes in patients (pts) with anthracyclines-pretreated metastatic breast cancer (MBC): sequential vs. combined therapy results from a MOSG randomised phase III trial. Proc Am Soc Clin Oncol 2006; 24: 18s (abstr 570).
16. Beslija S, Obralic N, Basic H, et al,. Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): TX vs.T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2006; 24: 18s (abstr 571).
17. Fountzilas G, Papadimitriou C, Dafni V, et al,. Dose-dense sequential chemotherapy with epirubicin and placlitaxel versus the combination, as first-line chemotherapy in advanced breast cancer: a randomized study conducted by the Hellenic cooperative oncology group. J Clin Oncol 2001; 19: 2232-9.
18. Alba E, Martin M, Ramos M, et al,. Multicentre randomised trial comparing sequential with concomitant administration of doxorubicin and docetaxel as frist-line treatment of metastatic breast cancer: a Spanich breast cancer research group (GEICAM/9903) phase III study. J Clin Oncol 2004; 22: 2587-93.
19. Cresta S, Grasselli G, Martoni A, et al,. A randomised phase II study of alternating (AA) versus sequential (SS) vs the combination (CC) of doxorubicin (A) and docetaxel (CT) as first-line CT in MBC patients. Proc Am Soc Clin Oncol 2001; 20:(abstr 190).
20. Koroleva I, Wojtukiewicz M, Zaluski J, et al,. Preliminary results of a phase II randomized trial of Taxotere and doxorubicin given in combination or sequentially as first line chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 2001; 20:(abstr 117).
21. Conte PF, Guarneri V, Bruzzi P, et al,. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma. Cancer 2004; 101: 704-12.
22. Tomova A, Brodowicz T, Tzekova V, et al,. Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine. Proc Am Soc Clin Oncol 2008; 26 (abstr 1106).